Papers 1986-1999
Publications 1999
Barnouin K, Fredersdorf S, Eddaoudi A, Mittnacht S, Pan LX, Du MQ, Lu X. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene. 18: 6388-6397, 1999.
Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR, Packham G. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 81:1042-1051, 1999
Codd JD, Salisbury JR, Packham G and Nicholson LJ. A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma. J. Pathol. 187: 549-555, 1999.
Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, Weiss RA, Lu X, Mittnacht S. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J 18: 644-653, 1999.
Hsieh J-K, Chan F, O'Connor DJ, Mittnacht S, Zhong S and Lu X. Rb regulates the apoptotic function of p53 via mdm2. Molecular Cell 3: 181-193, 1999
Kiermaier A, Gawn JM, Desbarats L, Saffrich R, Ansorge W, Farrell PJ, Eilers M and Packham G. DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene, 18: 7200-7211, 1999.
Lam EWF, Glassford J, van der Sman J, Banerji L, Pizzey AR, Thomas NSB and Klaus GGB. Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. Eur. J. Immunol, 29: 3380-3389, 1999.
MacCarthy-Morrogh L, Mouzakiti A, Townsend P, Brimmell M, Packham G. Bcl-2-related proteins and cancer. Biochem Soc Trans. 27:785-789, 1999.
Powell AJ, Darmon AJ, Gonos ES, Lam EWF, Peden KWC and Jat PS. Different functions are required for initiation and maintenance of immortalisation of rat embryo fibroblasts by SV40 large T antigen. Oncogene 18: 7343-7350, 1999.
Radkov SA, Touitou R, Brehm A, Rowe M, West M, Kouzarides T and Allday MJ. Epstein-Barr virus nuclear antigen (EBNA) 3C interacts with histone deacetylase to repress transcription. J. Virol 73: 5688-5697, 1999
Sala A, De Luca P, Saitta B, Lewis RE, Casella I, Watson R and Peschle C. B-Myb is an SP1 coactivator. Oncogene 18: 1333-1339, 1999
Sala, A and Watson R. B-Myb protein in cellular proliferation, transcription control and cancer: latest developments. J. Cell. Physiol. 179:245-250, 1999
Smith PD, Crossland S, Parker GA, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ and Crook T. Novel p53 mutants selected in BRCA-associated tumours which disassociate transformation suppression from other wild-type p53 functions. Oncogene 18: 2451-2459, 1999.
Spender LC, Cannell, EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G and Farrell PJ. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J. Virol 73: 4678-4688, 1999.
van der Sman J, Thomas NSB and Lam EWF. Modulation of E2F complexes during G0 to S phase transition in human primary B-lymphocytes. Journal of Biological Chemistry 274: 12009-12016, 1999
Voorhoeve PM, Watson RJ, Farlie PG, Bernards R and Lam EWF. Rapid dephosphorylation of p107 following UV irradiation. Oncogene 18: 679-688, 1999.
Yap DBS, Hsieh J-K, Chan FSG and Lu X. mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18: 7681-7689, 1999.
Publications 1998
Brimmell M, Mendiola R, Mangion J and Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 16: 1803-1812, 1998.
Cannell E, Farrell PJ and Sinclair AJ. Cell cycle arrest following exposure of Epstein-Barr virus immortalised B cells to gamma irradiation correlates with inhibition of cdk2 activity. FEBS Letters 439: 297-301, 1998.
Cludts I and Farrell PJ. Multiple functions within Epstein-Barr virus EBNA-3A protein. Journal of Virology, 72: 1862-1869, 1998.
Crook T, Brooks LA, Crossland S, Osin P, Barker K, Waller J, Philp E, Smith PD, Isik Y, Peto J, Parker GA, Allday MJ, Crompton MR and Gusterson BA. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA-1 and BRCA-2 associated breast cancers. Oncogene 17: 1681-1690, 1998.
Crook T, Parker GA, Rozycka M, Crossland S and Allday MJ. A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear: cytoplasmic shuttling defect. Oncogene 16: 1429-1441, 1998
Dahia PLM, Aguiar RCT, Honneger J, Fahlbush R, Lowe SLD, Lu X, Besser MG and Grossman AB. Mutation and expression analysis of the p27kip1 gene in corticotropin-secreting tumours. Oncogene 16: 69-76, 1998
Farrell, PJ. Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends in Microbiology 6: 175-177, 1998.
Gopalkrishnan RV, Lam EW-F and Kedinger C. The p53 tumor suppressor inhibits transcription of the TATA-less mouse DP1 promoter. J. Biological Chemistry 273: 10972-10978, 1998
Kirkham PA, Lam EWF, Takamatsu HH and Parkhouse RME. Transcription factor E2F controls the reversible gamma delta T cell growth arrest mediated through WC1. Journal of Immunology 161: 1630-1636,1998.
Lam EWF, Choi MSK, van der Sman J, Burbidge SA and Klaus GGB. Modulation of E2F activity via signalling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. J. Biological Chemistry 273: 10051-10057, 1998
Packham G . Mutation of BCL-2 family proteins in cancer. Apoptosis, 3: 75-82, 1998
Packham G, White EL, Eischen CM, Yang H, Parganas E, Ihle JN, Grillot DAM, Zambetti GP, Nunez G and Cleveland JL. Selective regulation of Bcl-XL by a Jak kinase dependent pathway is bypassed in murine hematopoietic malignancies. Genes and Development 12: 2475-2487, 1998.
Saville M and Watson RJ. B-Myb: a key regulator of the cell cycle. Advances in Cancer Research 72: 109-140, 1998.
Saville M and Watson RJ. The cell-cycle regulated transcription factor B-Myb is phosphorylated by Cyclin A/Cdk2 at sites that enhance its transactivation properties. Oncogene 17: 2679-2689, 1998.
Publications 1997
Evans T, Brooks L and Farrell PJ. A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated tumours. Gene Therapy 4: 264-267, 1997
Farrell PJ, Cludts I, Stuhler A. Epstein-Barr virus genes and cancer cells. Biomedicine and Pharmacotherapy 51: 258-267, 1997
Farrell PJ, Hollyoake M, Niedobitek G, Agathanggelou A, Morgan A and Wedderburn N. Direct demonstration of persistent EBV gene expression in peripheral blood of infected common marmosets and analysis of virus-infected tissues in vivo. J. Gen Virol 78: 1417-1424, 1997
Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ and Lu X. High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci USA 94: 6380-6385, 1997
Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K and Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes and Development 11: 1840-1852, 1997.
Klaus GGB, Choi MSK, Lam EW-F, Johnson-Leger C and Cliff JM. CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. International Review in Immunology 15: 5-31, 1997.
Lane S, Farlie P and Watson R. B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation. Oncogene 14: 2445-2453, 1997.
Packham G, Brimmell M and Cleveland JL. Mammalian cells express two differently localised Bag-1 isoforms generated by alternative translation. Biochemical Journal 328: 808-813, 1997P
Packham G and Cleveland JL. Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways. Oncogene 15: 1219-1232, 1997
Packham G, Lahti JM, Fee BE, Gawn JM, Coustan-Smith E, Douglas I, Campana D, Kidd VJ, Ghosh S and Cleveland JL. Fas activates NF-kB and induces apoptosis by signaling pathways distinct from those induced by TNF-a. Cell Growth & Differentiation 4: 130-139, 1997
Radkov SA, Bain M, Farrell PJ, West M, Rowe M and Allday MJ. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. Journal of Virology, 71: 8552-8562, 1997
Sala A, Kundu M, Casella I, Engelhard A, Calabretta B, Grasso L, Paggi MG, Giordano A, Watson RJ, Khalili K and Peschle C. Activation of human B-MYB by cyclins. Proc. Natl. Acad. Sci. USA 94: 532-536, 1997
Wangoo A, Shaw RJ, Diss TC, Farrell PJ, du Bois RM and Nicholson AG. Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr Virus infection. Thorax 52: 888-891, 1997.
Publications 1996
Allday MJ - Apoptosis and Epstein-Barr virus in B cells. Epstein-Barr Virus Report 3: 55-65, 1996
Evans TJ, Farrell PJ, Swaminathan S. Molecular genetic analysis of Epstein-Barr Virus Cp promoter function. Journal of Virology, 70: 1695-1705, 1996.
Bain M, Hale AD, Watson RJ, Farrell PJ, Allday MJ. Epstein-Barr virus nuclear antigen (EBNA) 3C is a powerful repressor of transcription when tethered to DNA. Journal of Virology, 70: 2481-2489, 1996.
Fredersdorf S, Milne A, Hall PA, Lu X. Immunochemical analysis of Waf1/Cip1 protein expression in normal human tissues using a panel of novel monoclonal antibodies American Journal of Pathology, 148: 825-835, 1996
Jenkins PJ, Farrell PJ. Are particular Epstein-Barr virus strains linked to disease? Seminars in Cancer Biology 7: 209-215, 1996
Robinson C, Light Y, Groves R, Mann D, Marais R, Watson RJ. Cell-cycle regulation of B-Myb protein expression: specific phosphorylation during the S phase of the cell cycle. Oncogene, 12: 1855-1864, 1996.
Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO Journal, 15: 827-838, 1996.
Sala A, Casella I, Bellon T, Calabretta B, Watson RJ and Peschle C. B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. Journal of Biological Chemistry, 271: 9363-9367, 1996.
Lu X, Burbidge SA, Griffin S, Smith H. Discordance between accumulated p53 protein level and its transcriptional activity in response to UV radiation. Oncogene 13: 413-418, 1996
Lyon JJ, Watson RJ. Interference of Myb transactivation activity by a conditional dominant negative protein: functional interference in a cytotoxic T-cell line results in G1 arrest. Gene 182: 123-128, 1996
Bennett JD, Farlie PG, Watson RJ - E2F binding is required but not sufficient for repression of B-myb promoter activity in quiescent fibroblasts. Oncogene 13: 1073-1082, 1996
Cannell EJ, Farrell PJ, Sinclair AJ. Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the imortalisation of primary B cells. Oncogene 13: 1413-1421, 1996
Wilding J, Vousden KH, Soutter WP, McCrea PD, Del Buono R, Pignatelli M. E-Cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Research 56: 5285-5292, 1996
Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, Allday MJ. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene, 13: 2541-2549, 1996
Wang M, Oppedijk BJ, Lu X, Van Duijn B, Schilperoot RA. Apoptosis in barley aleurone during germination and its inhibition by absicisic acid. Plant Molecular Biology 32: 1125-1134, 1996
Publications 1995
Allday MJ, Inman GJ, Crawford DH, Farrell PJ. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO Journal 14: 4994-5005, 1995.
Allday MJ, Sinclair A, Parker G, Crawford DH, Farrell PJ. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO Journal 14: 1382-1391, 1995.
Brooks L, Niedobitek G, Agathanggelou A, Farrell PJ. The expression of variant CD44 in nasopharyngeal carcinoma is unrelated to expression of LMP-1. American Journal of Pathology 146: 1102-1112, 1995.
Evans TJ, Jacquemin MG, Farrell PJ. Efficient superinfection of Group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology 206: 866-877, 1995.
Farrell PJ. Epstein-Barr virus immortalising genes. Trends in Microbiology, 3: 105-109, 1995.
Fuchs B, O'Connor D, Fallis L, Scheidtmann KH, Lu X. p53 phosphorylation mutants retain transcription activity. Oncogene 10: 789-793, 1995.
Hollyoake M, Stuhler A, Farrell P, Gordon J, Sinclair A. The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Research 55: 4784-4787, 1995.
Horner D, Lewis M, Farrell PJ. Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV related cancers. Intervirology, 38: 195-205, 1995.
Inman GJ, Farrell PJ. Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. Journal of General Virology 76: 2141-2149, 1995
Lam EWF, Bennett J, Watson RJ. Cell cycle regulation of human B-myb transcription. Gene 160: 277-281, 1995.
Lane DP, Midgley CA, Hupp TR, Lu X, Vojtesek B, Picksley SM. On the regulation of the p53 tumor suppressor and its role in the cellular response to DNA damage. Phil Trans Roy Soc Lond B. 347 (1319): 83-87, 1995.
Lyon JJ, Watson RJ. Conditional inhibition of erythroid differentiation by c-Myb/oestrogen receptor fusion proteins. Differentiation, 59: 171-178, 1995 .
Marston N, Jenkins JR and Vousden KH. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10: 1709-1715 , 1995.
Marston NJ, Vousden KH. Interactions of HPV encoded oncoproteins and regulators of cell growth. Apoptosis and Cell Cycle control in Cancer, ed NSB Thomas, pp 93-108. Bios Scientific Publishers, Oxford.
O'Connor DJ, Lam EWF, Griffin S, Zhong S, Leighton L, Burbidge SA, Lu X. Physical and functional interactions between p53 and the cell cycle cooperating transcription factors, E2F1 and DP1. EMBO Journal 14: 6184-6192, 1995.
Sinclair AJ, Farrell PJ. Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. Journal of Virology 69: 5461-5468, 1995
Sinclair AJ and Farrell PJ. Methods to study Epstein-Barr virus and p53 status in human cells. Methods in Molecular Genetics 7: 89-100, 1995.
Sinclair AJ, Palmero I, Holder A, Peters G, Farrell PJ. Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. Journal of Virology 69: 1292-1295, 1995.
Vousden KH. Interactions between papillomavirus proteins and tumor suppressor gene products. Advances in Cancer Research 64: 1-24
Vousden KH Regulation of cell cycle control by viral proteins. Seminars in Cancer Biology 6: 109-116, 1995.
Vousden KH Molecular events in cervical cancer. The Biology of Gynaecological Cancer, 110-118, 1995.
Publications 1994
Allday MJ, Farrell PJ. Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 1994; 68: 3491-8
Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 1994; 9: 1633-40
Beverley PCL, Sadovnikova E, Zhu X, Hickling J, Gao L, Chain B, Collins S, Crawford L, Vousden K, Stauss HJ. Strategies for studying mouse and human immune responses to human papillomavirus type 16. CIBA Found Symp 1994; 187: 78-96
Cook ID, Shanahan F, Farrell PJ. Epstein-Barr virus SM protein. Virology 1994; 205: 217-27
Crook T, Fisher C, Masterson PJ, Vousden KH. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 1994; 9: 1225-30
Crook T, Marston NJ, Sara EA, Vousden KH. Transcriptional activity by p53 correlates with suppression of growth but not transformation. Cell 1994; 79: 817-27
Crook T, Vousden KH. Interaction of HPV E6 with p53 and associated proteins. Biochem Soc Trans 1994; 22: 52-5
Farrell PJ, Sinclair AJ. Burkitt's lymphoma. In: Minson A, Neil J, McCrae M, eds. Viruses and cancer. Cambridge: CUP, 1994: 101-21 (Soc Gen Microbiol Symp; 51)
Farthing A, Masterson P, Mason WP, Vousden KH. Human papillomavirus detection by hybrid capture and its possible clinical use. J Clin Pathol 1994; 47: 649-52
Farthing AJ, Vousden KH. Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol 1994; 2: 170-4
Hickman ES, Picksley SM, Vousden KH. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 1994; 9: 2177-81
Jacquemin M, Sinclair AJ, Farrell PJ. Gene expression in Burkitt's lymphoma cells. In: Becker Y, Darai G, eds. Pathogenicity of human herpesviruses due to specific pathogenicity gene. Berlin: Springer-Verlag 1994: 283-97
Lam EWF, Morris JDH, Davies R, Crook T, Watson RJ, Vousden KH. HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J 1994; 13: 871-8
Lane DP, Lu X, Hupp T, Hall PA. The role of p53 protein in the apoptotic response. Philos Trans R Soc Lond B 1994; 345: 227-80
Lyon J, Robinson C, Watson R. The role of Myb proteins in normal and neoplastic cell proliferation. Crit Rev Oncog 1994; 5: 373-88
Marston NJ, Crook T, Vousden KH. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppression function. Oncogene 1994; 9: 2707-16
Pulverer BJ, Fisher C, Vousden KH, Littlewood T, Evan G, Woodgett JR. Site specific modulation c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 1994; 9: 59-70
Sinclair AJ, Jacquemin MG, Brooks L, Shanahan F, Brimmell M, (Rowe M), Farrell PJ. Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines. Virology 1994; 199: 339-53
Sinclair AJ, (Palmero I, Peters G), Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 1994; 13: 3321-8
Vousden KH. Cell transformation by human papillomaviruses. In: Minson A, Neil J, McCrae M, eds. Viruses and cancer. Cambridge: CUP, 1994: 27-46. (Soc Gen Microbiol Symp; 51).
Vousden KH, Farrell PJ. Viruses and human cancer. Br Med Bull 1994; 50: 560-81.
Publications 1993
Crook T, Farthing A. Human papillomavirus and cervical cancer. Br J Hosp Med 1993; 49: 131-2.
Davies R, (Hicks R), Crook T, Morris J, Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and p107 through sequences necessary for transformation. J Virol 1993; 67: 2521-8.
Davies RC, Vousden KH. Human papillomavirus (HPV) and cervical cancer. In: Yarnold J, Stratton M, McMillan T, eds. Molecular biology for oncologists. Amsterdam: Elsevier, 1993: 135-45.
Farrell PJ. Epstein-Barr virus. In: O'Brien SJ, ed. Genetic maps: locus maps of complex genomes. Book 1. Viruses. 6th ed. New York: Cold Spring Harbor Laboratory, 1993: 1.120-33.
Jacquemin MG, Sinclair AJ, Shanahan F, Farrell PJ. Analysis of p53, Rb, pim-1 and glucocorticoid receptor in Burkitt's lymphoma cell lines. Inserm Colloquium 1993; 225: 43-9.
Lam EW-F, Watson RJ. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J 1993; 12: 2705-13.
Lau R, (Middeldorp J), Farrell PJ. Epstein-Barr virus gene expression in oral hairy leukoplakia. Virology 1993; 195: 463-74.
Lau R, Sinclair A, Brimmell M, Farrell PJ. Epstein-Barr virus productive cycle gene expression in vivo. Inserm Colloquium 1993; 225: 203-9.
Morris JDH, Crook T, Bandara LR, Davies R, La Thangue NB, Vousden KH. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 1993; 8: 893-8.
Packham G, Brimmell M, Cook D, Sinclair AJ, Farrell PJ. Strain variation in Epstein-Barr virus immediate early genes. Virology 1993; 192: 541-50.
Palmero I, Holder A, Sinclair AJ, Dickson C, Peters G. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene 1993; 8: 1049-54.
Propst F, Storm SM, Rapp UR. Oncogenes coding for protein serine/threonine kinases: mos and raf. In: Neele BG, Kumar R, eds. The molecular basis of human cancer. Mount Kisco, NY:
Futura Scientific 1993; 1173-201.
Vousden KH. Human papillomaviruses. Int Antiviral News 1993; 1: 84-5.
Publications 1992
Allan GJ, Inman GJ, Parker BD, Rowe DT and Farrell PJ. Cell Growth effects of Epstein-Barr Virus leader protein. Journal of General Virology 73: 1547-1551, 1992.
Crook T and Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement in environmental carcinogens. EMBO Journal 11: 3935-3940, 1992.
Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ and Vousden KH. Clonal p53 mutation in primary cervical cancer: association with human papillomavirus-negative tumours. Lancet 339: 1070-1073, 1992.
Davies RC and Vousden KH. Functional analysis of human papillomavirus type 16 E7 by complementation with adenovirus E1a mutants. Journal of General Virology 73: 2135-2139, 1992.
Heath LA, Rosenberg MP, Thorogood P, Speight P and Propst F. Harderian gland hyperplasia in c-mos trangsenic mice. International Journal of Cancer 51: 310-314, 1992.
James ND and Crook TC. Viruses and penile cancer. In: Urological Oncology, Waxman J and Williams G (eds). Edward Arnold, Sevenoaks, UK. pps. 43-47, 1992.
James ND, Kingston JE, Plowman PN, Meller S, Pinkerton CR, Barrett A, Sandland R, McElwain TJ and Malpas JS. Outcome of children with relapsed and resistant Hodgkin's Disease. British Journal of Cancer 66: 1155-1158, 1992.
James ND and Sikora K, Immunotherapy of tumours. In: Encyclopedia of Immunology, Roitt I and Delves PJ (eds). Academic Press, London. Pps. 857-859, 1992.
Lam EW-F, Robinson C and Watson RJ. Characterization and cell-cycle-regulated expression of mouse B-myb. Oncogene 7: 1885-1890, 1992.
Lau R, Packham G and Farrell PJ. Differential Splicing of Epstein-Barr Virus Immediate-Early RNA. Journal of Virology 66: 6233-6236, 1992.
Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH and Laimins LA. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO Journal 11: 3045-3052, 1992.
Propst F, Cork LC, Kovatch RM, Kasenally AB, Wallace R and Rosenberg MP. Progressive hind limb paralysis in mice carrying a v-Mos transgene. Journal of Neuropathology and Experimental Neurology 51: 499-505, 1992.
Rooney CM, Brimmell M, Buschle M, Allen G, Farrell PJ and Kolman JL. Host cell and EBNA-2 regulation of Epstein-Barr virus latent cycle promoter activity in B lymphocytes. Journal of Virology 66: 496-504, 1992.
Rowe A and Propst F. Ets-1 and Ets-2 proto-oncogene expression in theca cells of the adult mouse ovary. Experimental Cell Research 202: 199-202, 1992.
Schulz N, Propst F, Rosenberg MP, Linnoila RI, Paules RS, Kovatch R, Ogiso Y and Vande Woude G. Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 sydrome. Cancer Research 52: 450-455, 1992.
Schulz N, Propst F, Rosenberg MM, Linnoila RI, Paules RS, Schulte D and Vande Woude G. Patterns of Neoplasia in c-Mos Transgenic Mice and their Relevance to Multiple Endocrine Neoplasia. Henry Ford Hospital Medical Journal. 40: 307-311, 1992.
Sinclair AJ and Farrell PJ. Epstein-Barr Virus Transcription Factors. Cell Growth and Differentiation 3: 557-563, 1992.
Sinclair AJ, Brimmell M and Farrell PJ. Reciprocal antagonism of steroid hormones and BZLF1 in switch between EBV latent and productive cycle gene expression. Journal of Virology 66: 70-77, 1992.
Vousden KH. (1992) Human papillomavirus transforming genes. Seminars in Virology. Teich N (ed). Saunders Scientific Publications 2: 307-317, 1992.
Waxman J, Barton C, Biruls R, James N, Harrison M, Mee D, Sikora K, Colbeck R, Abel P and Williams G. Bladder cancer; Inter-relationships between chemotherapy and radiotherapy. British Journal of Urology 69: 151-155, 1992.
Wrede D, Luqmani YA, Coombes RC and Vousden KH. Absence of HPV 16 and 18 DNA in breast cancer. British Journal of Cancer 65: 891-894, 1992.
Publications 1991
Banks L, Moreau F, Vousden KH and Matlashewski G. Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. Journal of Immunology 146: 2037-2042, 1991.
Crook T, Fisher C and Vousden KH. Modulation of immortalizing properties of HPV16 E7 by p53 expression. Journal of Virology 65: 505-510, 1991.
Crook T, Tidy JA and Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547-556, 1991.
Crook T, Wrede D and Vousden KH. P53 point mutation in human papillomavirus negative cervical carcinoma cell lines. Oncogene 6: 873-875, 1991.
Crook T, Wrede D, Crawford L, Scholefield J and Vousden KH. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene 6: 1251-1257, 1991.
Farrell PJ, Allan GJ, Shanahan F, Vousden KH and Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO Journal 10: 2879-2887, 1991.
Grinberg D, Thurlow J, Watson R, Smith R, Peters G and Dickson C. Transcriptional regulation of the int-2 gene in embryonal carcinoma cells. Cell Growth and Differentiation 2: 137-143, 1991.
Howe KM and Watson RJ. Nucleotide preferences in sequence-specific recognition of DNA by c-myb protein. Nucleic Acids Research 14: 3913-3919, 1991.
Kouzarides T, Packham G, Cook A and Farrell PJ. The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 6: 195-204, 1991.
Parker BD and Farrell PJ. The productive cycle detect in raji EBV is not solely due to absence of the BALF2 gene. In: Epstein-Barr virus and Human Disease. Abalshi DV, Huang AT, Pagano JS, Pearson GR and Yang CS (eds). Humana Press, New York. Pps. 13-18, 1991.
Propst F, Cork LC, Kovatch RM, Vande Woude GF, Rosenberg MP, Progressive neurodegenerative changes in transgenic mice overexpressing Mos oncogenes in the brain. In: Biology Psychiatry (vol 2), Racagni G, Brunello N and Fukuda T (eds). Excerpta Medica, Amsterdam, pps. 443-445, 1991.
Sinclair AJ, Brimmell M, Shanahan F and Farrell PJ. Pathways of Activation of the Epstein-Barr Virus Productive Cycle. Journal of Virology 65: 2237-2244, 1991.
Vousden KH. Human papillomavirus oncoproteins. In: Seminars in Cancer Biology. Evan GJ (ed). Saunders Scientific Publications, London1:pps. 415-424, 1990.
Vousden KH. Papillomaviruses and assays for transforming genes. In: Methods in Molecular Virology. Collins M (ed). Humana Press Inc., USA. 8:pps. 159-174, 1991.
Vousden KH, Wrede D and Crook T. HPV oncoprotein function-releasing the brakes on cell growth control? Papillomavirus reports 2: pps. 1-6, 1991.
Wrede D, Tidy JA, Crook T, Lane D and Vousden KH. Expression of RB and p53 Proteins in HPV-Positive and HPV-Negative Cervical Carcinoma Cell Lines. Molecular Carcinogenesis 4: 171-175, 1991.
Young LS, Lau R, Rowe M, Niedobitek G, Packham G, Shanahan F, Rowe DR, Greenspan D, Greenspan JS, Rickinson AB and Farrell PJ. Differntiation-Associated Expression of the Epstein-Barr Virus BZLF1 Transactivator Protein in Oral Hairy Leukoplakia. Journal of Virology 65: 2868-2874, 1991.
Publications 1990
Banks L, Barnett SC and Crook T. HPVI6 E7 functions at the G1 to S phase transition in the cell cycle. Oncogene 5: 833-837, 1990.
Banks L, Edmonds C and Vousden KH. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity. Oncogene 5: 1383-1389, 1990.
Buschle M, Brenner MK, Chen ISY, Drexler HG, Gignac SM and Rooney CM. Transfection and gene expression in normal and malignant primary B lymphocytes. Journal of Immunological Methods 133: 77-86, 1990.
Chesters PM, Vousden KH, Edmonds C and McCance DJ. Analysis of human papillomavirus type 16 open reading frame E7 immortalising function in rat embryo fibroblast cells. Journal of General Virology 71: 449-453, 1990.
Doorbar J, Parton A, Hartley KO, Banks L, Crook T, Stanley M and Crawford L. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 178: 254-262, 1990.
Farrell PJ. Epstein-Barr virus. In: Genetic Maps O'Brien S (ed). Cold Spring Harbour Publications, USA. 5: pps. 102-114, 1990.
Lau R, Sankar K, O'Mahony C, Pocklington S, McManus TJ and Bignell CJ. Vaginal Infections in general practise. Practical Nurse (supplement), 1990.
Lau RKW. Acquired immunodeficiency syndrome and Epstein-Barr virus. International Journal of Sexually Transmitted Diseases and Acquired Immune deficiency Syndrome. 1: 318-320, 1990.
Packham G, Economou A, Rooney CM, Rowe DT and Farrell PJ. Structure and function of the Epstein-Barr virus BZLF1 protein. Journal of Virology 64: 2110-2116, 1990.
Parker BD, Bankier A, Satchwell S, Barrell BG and Farrell PJ. Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology 179: 339-346, 1990.
Propst F. The techniques of molecular biology: introduction to principles and applications. In: Balliere's Clinical Gastroenterology. Ciclitira P (ed). Saunders Publications, London. 4: pps. 1-22, 1990.
Propst F, Rosenberg MP, Cork LC, Kovatch RM, Rauch RM, Westphal H, Khillan J, Schulz NT, Vande Woude GF and Newman PE. Neuropathological changes in transgenic mice carrying copies of a transcriptionally activated Mos protooncogene. Proceedings of the National Academy of Sciences of the United States of America. 87: 9703-9707, 1990.
Rowe DT, Hall L, Joab I and Laux G. Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes. Journal of Virology 64: 2866-2875, 1990.
Schiller JT, Vousden KH, Hawley-Nelson P, Barbosa M, Edmonds C, Androphy E and Lowy D. Analysis of papillomavirus E6 and E7 gene products. Papillomaviruses. Howley PM and Broker TR (eds). Wiley-Liss Inc., New York. pps 271-283, 1990.
Vousden KH. Cellular transformation by human papillomavirus type 16. Modern trends in aetiology and management of CIN. Singer A and Harten-Ash VJ (eds). Duphar Medical Relation, South Hampton. Pps. 13-17, 1990.
Publications 1989
Allan G and Rowe DT. Size and stability of the Epstein-Barr virus major internal repeat (IR-1) in Burkitt's lymphoma and lymphoblastoid cell lines. Virology 173: 489-498, 1989.
Barbosa MS Edmonds C Fisher C Schiller JT Lowy DR and Vousden KH. The region of the HPV E7 oncoprotein homologous to adneovirus E1a and SV40 large T antigen contains separable domains for RB binding and casein kinase II phosphorylation. EMBO J. 9: 153-160, 1989.
Crook T, Banks L, Smith K and Crawford L. Amplification and overexpression of c-myc protooncogene correlates with loss of glucocorticoid dependence in rodent cells transformed by HPV16. Molecular Carcinogenesis. 2: 308-313, 1989.
Crook T, Morgenstern JP, Crawford L and Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 8: 513-519, 1989.
Cunningham D. Antiemetic therapy. In: Treatment of Cancer (eds. Sikora K and Halnan KE) Chapman and Hall; 41: 811-817, 1989.
Cunningham D, Hickish T, Rosin RD, Sauven P, Baron JH, Farrell PJ and Isaacson P. Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet (i) 695-697, 1989.
Cunningham D, Turner A, Hawthorn J and Rosin RD. Odansetron with and without dexamethasone to treat chemotherapy induced emesis. Lancet (i) 1323, 1989.
Dowsett M, Cunningham D, Haydock A and Coombes RC. Experience with intermediate dose (110-120mg/m) epirubicin. Cancer. Chem. Pharm. 24: 61-64, 1989.
Dowsett M, Cunningham D, Stein R, Evans S, Dehenin L, Hedley A, Coombes RC. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Research 49: 1306-1312, 1989
Edmonds C and Vousden KH. A point of mutational analysis of Human papillomavirus type 16 E7 protein. J. Virol. 63: 2650-2656, 1989.
Farrell PJ. Epstein-Barr virus genome. Advances in Viral Oncology. 8: 103-132 Ed. G. Klein, Raven Press, New York. 1989.
Farrell PJ, Rowe DT, Rooney CM and Kouzarides T. Epstein-Barr virus BZLF1 transactivator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8: 127-132, 1989.
Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR and Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalise primary human foreskin keratinocytes. EMBO J. 8: 3905-3910, 1989.
Hickish T and Cunningham D. Detection of t(14:18) in paraffin-embedded lymphoma tissue. Lancet (i) 1131-1132 and (ii) 218-219. 1989.
Laux G, Economou A and Farrell PJ. The terminal protein gene 2 of Epstein-Barr virus is transcribed from a subdirectional latent promoter region. J. Gen. Virol. 70: 3079-3084, 1989.
Lees E, Osborn K, Banks L and Crawford L. Transformation of primary BRK cells by human papillomavirus type 16 and EJ-ras is increased by overexpression of the viral E2 protein. J. Gen. Virol. 71: 183-193, 1990.
Pau L, Diss TC, Cunningham D and Isaacson PG. The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT). Am. J. Pathol. 135: 7-11, 1989.
Propst F, Vande Woude GF, Jenkins NA, Copeland NG, Hee BK, Hunt PA and Eicher EM. The Mos proto-oncogene maps near the centromere on mouse chromosome 4. Genomics 5: 118-123, 1989.
Rooney CM, Rowe DT, Ragot T and Farrell PJ. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63: 3109-3116, 1989.
Rowe DT and Clarke JR. The type-specific epitopes of the Epstein-Barr virus nuclear antigen 2 are near the carboxy terminus of the protein. J. Gen. Virol. 70: 1217-1229, 1989.
Tidy JA. A study of the value of measuring maternal serum alphafetoprotein for the ante-natal diagnosis of neural tube defects. Archives of Gynaecology and Obstetrics 244: 133-136, 1989.
Tidy JA and Farrell PJ. Viruses and cervical neoplasia. In Waxman J. and Sikora K. (eds) The Molecular Biology of Cancer. Blackwells Scientific. 101-112 (1989).
Tidy JA and Farrell PJ. Viruses and human cancer. Recent Advances in Histopathology 14: 23-41 Eds. P.P. Anthony and R.N.M. Macween, Churchill Livingston, London. 1989.
Tidy JA, Parry GCN, Ward P, Coleman DV, Peto J, Malcolm ADB and Farrell PJ. High rate of HPV16 infection in the female population. Lancet. (i) 434 (1989).
Tidy JA, Vousden KH and Farrell PJ. A new and sensitive method of screening for human papillomavirus infection. Obstetrics and Gynaecology 74: 410-414, 1989.
Tidy JA, Vousden KH and Farrell PJ. Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (i) 1225-1227 and (ii) 1535, 1989.
Tidy JA, Vousden KH, Mason P, and Farrell PJ. A novel deletion within the upstream regulatory region of episomal human papillomavirus type 16. J. Gen. Virol. 70: 999-1004, 1989.
Vousden KH. Human Papillomaviruses and cervical cancer. Cancer Cells, a monthly review 1: 43-49, 1989.
Vousden KH, Androphy EJ, Schiller JT and Lowy DR. Mutational Analysis of Bovine Papillomavirus E6 gene. J. Virol. 63: 2340-2345, 1989.
Vousden KH and Jat PS. Functional similarity between HPV16 E7, SV40 large T and adneovirus E1a proteins. Oncogene 4: 153-158, 1989.
Publications 1988
Anderson MC, Tidy JA. The aetiology of cervical cancer. In Anderson MC (ed) Systematic Pathology (2nd ed.) Churchill Livingstone.
Cunningham D. The treatment of emesis induced by cytotoxic drugs. Hospital Update.
Cunningham D. Gastric Cancer - The recognition of a chemosensitive tumour. Editorial British Journal of Cancer 58: 695-699, 1988.
Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Kaye SB, Soukop M. A randomised trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in treatment of emesis induced by chemotherapy regimens containing cisplatin or cisplatin analogues. European Journal of Cancer 24: 685-689, 1988.
Cunningham D, Cummings J, Blackie RB, McTaggert C, Banham SW, Kaye SB, Stuart JFB, Welsh J, Soukop M. Interactive pharmacokinetics of cyclophosphamide and etoposide when given in high dose. Medical Oncology and Tumour pharmacology 5: 117-123, 1988.
Cunningham D, Hickish T, and Coombes T. The treatment of solid tumours with high dose epirubicin. Pharmorubicin Update 88 symposium proceedings, 2-5 (1988).
Farrell PJ and Barrell BG. Gene expression of Epstein-Barr virus in, The Herpesviruses vol 5 (ed) B. Roizman. Plenum Press.
Farrell PJ, Tidy JA. Viruses and Cancer. In Recent Advances in Histopathology 14: 23-41. Churchill Livingstone, 1988.
Hatfull G, Bankier AT, Barrell BG and Farrell PJ. Sequence analysis of Raji Epstein-Barr Virus DNA. Virology 164: 334-340, 1988
Hickish T and Cunningham D. Gene rearrangement in B-cell lymphomas. In: Genes and Cancer. Carney D. and Sikora, K. (eds).
Hickish T, Cunningham D, Haydock A and Coombes R. Experience with intermediate dose (10-120mg/m2) epirubicin - a phase 1 report. Cancer Chemotherapy and pharmacology 24: 61-64, 1988.
Isles SR, Hickish T and Cunningham D. Chemotherapy related pulmonary embolus recognised. British Medical Journal 297: 854, 1988.
Laux G, Perricaudet M and Farrell PJ. A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circulisation of the linear viral genome. EMBO J. 7: 769-774 (1988).
Rooney C, Taylor N, Countryman J, Jenson H, Kolman J and Miller G. Genome rearrangements activate the Epstein-Barr virus gene whose products disrupt latency. Proc. Natl. Acad. Sci. USA 85: 9801-9806 (1988).
Tidy JA. HPV16 DNA integration and tumour maintenance. In "The aetiology of cervical neoplasia". Duphar Symposium.
Tidy JA, Farrell PJ and Mason WP. HPV-16 DNA sequences are present in disease free regional lymph nodes from patients with cervical carcinoma. 26th Annual Meeting of the British Society for Clinical Cytology.
Tidy JA and Mason WP. Endometrioid carcinoma of the ovary: A retrospective study. British Journal of Obstetrics and Gynaeocology 95: 1165-1169 (1988).
Vousden KH, Doniger J, Dipaolo JA and Lowy DJ. The E7 Open Reading Frame of Human Papillomavirus Type 16 encodes a transforming gene. Oncogene Research 3: 167-175 (1988).
Publications 1987
Biggin M, Bodescot M, Perricaudet M and Farrell PJ. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. Journal of Virology. 61: 3120-3132, 1987.
Bodescot M, Perricaudet M and Farrell PJ. A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. Journal of Virology. 61: 3424-3430, 1987.
Farrell PJ. Epstein-Barr virus (B95-8 strain) in Genetic Maps (S. O'Brien, ed) 4: 99-107, 1987. Cold Spring Harbour Publications, New York.
Jenson HB, Farrell PJ and Miller G. Sequences of the Epstein-Barr virus (EBV) large internal repeat form the center of a 16 kilobase pair palindrome of EBV (P3HR1) heterogeneous DNA. Journal of Virology. 61: 1495-1506, 1987.
Joab I, Rowe DT, Bodescot M, Nicolas JC, Farrell PJ and Perricaudet M. Mapping of the gene coding for Epstein-Barr virus determined nuclear antigen EBNA3 and its transient over-expression in a human cell line by using an adneovirus expression vector. Journal of Virology 61: 3340-3344, 1987.
Rowe DT, Farrell PJ and Miller IG. Novel Epstein-Barr virus nuclear antigens recognised by human sera in latently infected lymphocytes. Virology, 156: 153-162, 1987.
Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H and Rickinson AB. Differences in B cell growth phenotype reflect novel patterns of the Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO Journal 6: 2743-2751, 1987.
Wallace LE, Young LS, Rowe M, Rowe DT and Rickinson AB. Epstein-Barr virus-specific T-cell recognition of B cell transformants expressing different EBNA-2 antigens. International Journal of Cancer 39: 373-379, 1987.
Publications 1986
Gibson TJ, Barrell BJ and Farrell PJ. Coding content and expression of the EBV B95-8 genome in the region from base 62248 to 82920. Virology 152: 136-148, 1986.
Rowe DT, Rowe M, Evan G, Wallace LE, Farrell PJ and Rickinson AB. Restricted expression of EBV latent genes and T-lymphocyte detected membrane antigen in Burkitt's lymphoma cells. EMBO Journal 5: 2599-2607, 1986.
